SPAC212.08c Antibody

What is SPAC212.08c and why is it significant in research?

SPAC212.08c is a gene in Schizosaccharomyces pombe (fission yeast) located in subtelomeric regions. It is normally repressed through heterochromatic silencing in wild-type cells. Research has shown this gene becomes significantly upregulated (approximately 60-fold) in set2Δ cells, indicating it is normally under tight epigenetic control .

The gene serves as an excellent model for studying heterochromatin formation and maintenance, particularly at subtelomeric regions. Its expression levels are highly responsive to changes in chromatin modification pathways, making it a valuable reporter for epigenetic regulation studies.

What experimental applications is the SPAC212.08c antibody suitable for?

According to the antibody datasheet, the SPAC212.08c antibody (product code CSB-PA884653XA01SXV) has been tested and validated for:

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Western Blotting (WB)

The antibody is a polyclonal antibody raised in rabbit against a recombinant SPAC212.08c protein immunogen and is specifically designed for detecting the protein in Schizosaccharomyces pombe (strain 972 / ATCC 24843) samples .

What are the optimal storage and handling conditions for SPAC212.08c antibody?

The SPAC212.08c antibody should be stored at either -20°C or -80°C upon receipt. Repeated freeze-thaw cycles should be avoided as they can degrade the antibody and reduce its effectiveness .

The antibody is supplied in liquid form with a storage buffer containing:

• 50% Glycerol

• 0.01M PBS, pH 7.4

• 0.03% Proclin 300 (preservative)

For optimal stability, aliquoting the antibody into smaller volumes before freezing is recommended to minimize freeze-thaw cycles. When handling the antibody, standard laboratory practices for working with proteins should be followed, including using clean pipette tips and maintaining a cold chain during experimental procedures.

What are the recommended Western blotting conditions for SPAC212.08c antibody?

Based on Western blotting protocols used for similar S. pombe proteins, the following conditions are recommended:

• Sample preparation:

  • Extract proteins using buffer containing 50 mM Tris–HCl pH 8.0, 300 mM NaCl, 1 mM EDTA, 0.1% NP-40, 1 mM Mg-acetate, 1 mM imidazole, 10% glycerol, complete protease and phosphatase inhibitors, and 1 mM PMSF .

  • Use a ratio of 1 g of yeast powder to 1 ml of extraction buffer.

  • Extract for 20 min at 4°C and clear by centrifugation (41,000 g for 10 min at 4°C).

• Electrophoresis and transfer:

  • Use standard SDS-PAGE for protein separation.

  • Transfer to PVDF membrane (0.45 μm).

• Immunodetection:

  • Recommended antibody dilution: 1:2000 for primary antibody

  • Recommended secondary antibody: Anti-rabbit IgG conjugated to HRP at 1:10,000 dilution

  • Incubate with primary antibody overnight at 4°C for optimal results

• Signal detection:

  • Use appropriate chemiluminescence reagents for HRP detection.

  • For quantitative analysis, capture digital images and analyze using software such as ImageJ.

What controls should be included when validating SPAC212.08c antibody specificity?

To validate SPAC212.08c antibody specificity, several controls should be implemented:

• Genetic controls:

  • Compare wild-type S. pombe and a SPAC212.08c deletion strain (if available).

  • Include set2Δ mutant samples where SPAC212.08c expression increases ~60-fold as a positive control .

  • Use set2Δ mst2Δ double mutant samples where expression returns to wild-type levels .

• Antibody validation controls:

  • Perform peptide competition assay using the recombinant SPAC212.08c protein.

  • Include isotype-matched non-specific IgG as a negative control.

  • Use tagged version of SPAC212.08c (if available) for validation with anti-tag antibodies.

• Technical controls:

  • Verify band size matches the predicted molecular weight of SPAC212.08c.

  • Include loading controls such as tubulin or actin.

  • Perform titration experiments with varying antibody concentrations.

How can SPAC212.08c antibody be utilized to study heterochromatin regulation?

SPAC212.08c antibody serves as a valuable tool for investigating heterochromatin dynamics:

• Chromatin Immunoprecipitation (ChIP) studies: Use SPAC212.08c antibody to analyze protein localization at specific genomic loci. Research has shown that H3K9me2 levels vary at SPAC212.08c in different genetic backgrounds, suggesting dynamic regulation .

• Comparative analysis across genetic backgrounds: The table below summarizes key differences in SPAC212.08c regulation between wild-type and mutant cells:

• Co-immunoprecipitation experiments: Identify protein complexes that interact with SPAC212.08c, potentially revealing its role in heterochromatin formation.

• Immunofluorescence microscopy: Visualize the subnuclear localization of SPAC212.08c protein and determine if it colocalizes with known heterochromatin markers.

What insights has SPAC212.08c research contributed to our understanding of epigenetic regulation?

Studies involving SPAC212.08c have revealed several key insights into epigenetic mechanisms:

• Set2-dependent silencing: Research has established that deletion of set2+ causes pronounced upregulation of SPAC212.08c (60-fold increase), demonstrating that the H3K36 methyltransferase Set2 is critical for silencing subtelomeric genes .

• Antagonistic histone modifier relationship: When mst2+ is deleted in set2Δ cells, silencing of SPAC212.08c is completely restored, revealing that Mst2 (a histone acetyltransferase) counteracts Set2-mediated silencing .

• Histone modification interplay: ChIP-qPCR studies have shown that H3K9me2 levels at SPAC212.08c decrease in set2Δ cells but increase in mst2Δ and set2Δ mst2Δ cells , demonstrating that Mst2 counteracts H3K9me2 deposition in a context-dependent manner.

• Sequential regulation model: The findings suggest a model where Set2-deposited H3K36me3 sequesters the Mst2 complex (through the PWWP domain protein Pdp3), preventing it from antagonizing heterochromatin formation at subtelomeric regions like SPAC212.08c .

How does SPAC212.08c expression correlate with heterochromatin marks?

SPAC212.08c expression shows a strong inverse correlation with heterochromatin marks, particularly H3K9me2:

• Inverse relationship with H3K9me2: ChIP-qPCR analyses show that when H3K9me2 levels decrease at the SPAC212.08c locus (as in set2Δ cells), there is a corresponding increase in SPAC212.08c expression . Conversely, when H3K9me2 levels increase (as in mst2Δ cells), SPAC212.08c remains silenced.

• Moderate H3K9me2 levels: SPAC212.08c exhibits "intermediate" H3K9me2 levels compared to other heterochromatic regions, suggesting it might be at a heterochromatin-euchromatin boundary with more dynamic regulation .

• HP1 protein recruitment: Research has shown that occupancy of heterochromatin proteins Swi6 and Chp2 (HP1 homologs) at SPAC212.08c correlates with H3K9me2 levels, being slightly decreased in certain mutants (e.g., mrc1 mutants) .

• H3K14 acetylation dynamics: In addition to H3K9me2, regulation of H3K14 acetylation also appears to play a role in SPAC212.08c silencing, with temporal dynamics during the cell cycle .

What are the technical challenges in studying SPAC212.08c in heterochromatic regions?

Detecting and analyzing SPAC212.08c in heterochromatic regions presents several challenges:

• Low basal expression: SPAC212.08c is normally silenced in wild-type cells, making protein detection challenging without sensitive methods .

• Variable expression patterns: The dramatic differences in SPAC212.08c expression between genetic backgrounds (wild-type vs. set2Δ vs. set2Δ mst2Δ) necessitates careful experimental design .

• Chromatin accessibility: The heterochromatic nature of the SPAC212.08c locus creates technical challenges for techniques like ChIP, as heterochromatin can be less accessible to antibodies and enzymatic treatments.

• Antibody cross-reactivity concerns: Some antibodies used in related research (e.g., anti-H3K36me3) show limited cross-reactivity with H3K9me2 , highlighting the importance of rigorous antibody validation.

• Temporal dynamics: Research suggests heterochromatin regulation has temporal aspects, with certain factors influencing H3K14ac levels in specific cell cycle phases , adding complexity to experimental design.

How can ChIP-seq with SPAC212.08c antibody be optimized for heterochromatin studies?

When performing ChIP-seq with SPAC212.08c antibody in heterochromatic regions, consider these optimization strategies:

• Chromatin preparation enhancements:

  • Implement dual crosslinking: Use disuccinimidyl glutarate (DSG) followed by formaldehyde to stabilize protein-protein interactions.

  • Optimize sonication specifically for heterochromatic regions, which resist fragmentation due to their compact nature.

  • Consider combining enzymatic digestion (MNase) with sonication for more uniform fragmentation.

• Immunoprecipitation optimization:

  • Increase antibody concentration and incubation time for more efficient capture of heterochromatic regions.

  • Include blocking agents to reduce background.

  • Consider sequential ChIP (Re-ChIP) when studying co-occupancy with other factors.

• Advanced sequencing approaches:

  • Use paired-end sequencing with longer read lengths (≥100 bp) to improve mapping in repetitive regions.

  • Increase sequencing depth (minimum 30-40 million reads) to ensure sufficient coverage.

  • Implement unique molecular identifiers (UMIs) to correct for PCR duplicates.

• Specialized bioinformatic analysis:

  • Use mappers designed for repetitive regions.

  • Implement multi-mapping read strategies rather than discarding these reads.

  • Apply peak calling parameters optimized for broad, diffuse signals typical of heterochromatin.

What controls are essential for ChIP experiments with SPAC212.08c antibody?

When conducting ChIP with SPAC212.08c antibody, include these controls:

• Input controls:

  • Reserve 5-10% of chromatin before immunoprecipitation.

  • Process alongside ChIP samples to normalize for biases.

• Antibody specificity controls:

  • Use non-specific rabbit IgG as negative control.

  • Include SPAC212.08c deletion strain controls if available.

  • Consider peptide competition assays to verify binding specificity.

• Genomic region controls:

  • Design primers for regions where SPAC212.08c is expected to bind.

  • Include primers for regions where SPAC212.08c should not bind.

  • Use euchromatic genes (highly transcribed) as negative controls.

• Genetic background controls:

  • Include wild-type cells as baseline.

  • Use set2Δ cells (60-fold increased expression) as positive control .

  • Include set2Δ mst2Δ cells where silencing is restored .

• Procedural controls:

  • Verify chromatin fragmentation to 200-500 bp size.

  • Include mock IP (no antibody) control.

  • Perform qPCR on dilution series of input for standard curve.

How can weak or non-specific SPAC212.08c signal be troubleshooted?

When encountering weak or non-specific signals, implement these troubleshooting approaches:

For Weak Signal Issues:

• Optimize antibody conditions:

  • Increase primary antibody concentration (try 1:1000 or 1:500 instead of 1:2000) .

  • Extend primary antibody incubation time to overnight at 4°C.

  • Use more sensitive detection systems (enhanced chemiluminescence).

• Improve sample preparation:

  • Optimize protein extraction using the buffer described in section 1.4.

  • Increase protein concentration in samples.

  • Use fresh samples, as SPAC212.08c might be unstable during storage.

• Enhance target abundance:

  • Use set2Δ mutant strains where SPAC212.08c expression increases ~60-fold as positive control .

  • Consider using overexpression systems for functional studies.

For Non-specific Signal Issues:

• Increase stringency:

  • Test different blocking agents (BSA, non-fat dry milk, commercial reagents).

  • Increase salt concentration in washing buffers (300 mM NaCl).

  • Add 0.1% SDS to washing buffers for Western blots.

• Enhance antibody specificity:

  • Pre-absorb antibody with extract from a SPAC212.08c deletion strain.

  • Consider further affinity purification using recombinant SPAC212.08c.

  • Test alternative antibody lots if available.

How can SPAC212.08c antibody be used for reporter gene assays in heterochromatin studies?

SPAC212.08c antibody can be effectively utilized in reporter gene studies to investigate heterochromatin dynamics:

• Experimental design considerations:

  • Use reporter genes (ura4+, ade6+) inserted near SPAC212.08c to monitor silencing effects.

  • Research has shown that reporter genes in subtelomeric regions (e.g., ura4+ inserted into SPAC212.07c) effectively monitor silencing status .

  • Design constructs with varying distances from heterochromatin boundaries to study spreading effects.

• Integrated approach methodology:

  • Combine reporter gene expression analysis with ChIP experiments using SPAC212.08c antibody.

  • Correlate protein levels/localization with reporter gene repression/activation.

  • Analyze the relationship between SPAC212.08c occupancy and heterochromatin mark distribution.

• Heterochromatin barrier studies:

  • Use SPAC212.08c antibody along with ChIP-seq for heterochromatin marks to map domain boundaries.

  • Monitor how these boundaries shift in different genetic backgrounds or conditions.

  • Correlate boundary shifts with changes in reporter gene expression.

What interactions between SPAC212.08c and chromatin-modifying factors have been identified?

Research has revealed several interactions between SPAC212.08c regulation and chromatin modifiers:

• Set2-dependent regulation: Set2, an H3K36 methyltransferase, plays a critical role in maintaining SPAC212.08c silencing. In set2Δ cells, SPAC212.08c expression increases dramatically (~60-fold) .

• Mst2 antagonistic activity: The histone acetyltransferase complex Mst2C antagonizes silencing at SPAC212.08c. Deletion of mst2+ in set2Δ cells completely restores silencing .

• PWWP domain protein interaction: Pdp3, a PWWP domain protein that binds H3K36me3, sequesters Mst2C away from heterochromatin. Combining deletions of set2+ and pdp3+ results in an epistatic silencing phenotype .

• Mst2 complex components: The intact Mst2 complex (including Nto1 and Ptf2) is required to trigger silencing defects at SPAC212.08c in set2Δ cells. Deletion of either component suppresses the silencing defect .

• Potential Mrc1 interactions: Research suggests Mrc1 may contribute to SPAC212.08c regulation through recruitment of the SHREC complex (containing the HDAC Clr3), particularly during late S phase .

How can SPAC212.08c be studied in the context of genome-wide gene regulatory networks?

SPAC212.08c can be incorporated into genome-wide regulatory network studies using several approaches:

• Integrative network analysis:

  • Include SPAC212.08c in cross-species common gene regulatory network inference .

  • Apply co-inertia analysis and Hungarian algorithm matching to identify conserved regulatory relationships .

  • Use dynamic Bayesian networks to model temporal dynamics of SPAC212.08c regulation.

• Multi-dimensional data integration:

  • Combine transcriptomic data (RNA-seq) with chromatin state information (ChIP-seq) to build comprehensive regulatory models.

  • Use packages like MultiRNAflow for integrated analysis of temporal RNA-seq data .

  • Correlate SPAC212.08c expression patterns with global changes in heterochromatin structure.

• Comparative genomics approaches:

  • Compare SPAC212.08c regulation across different yeast species to identify conserved regulatory mechanisms.

  • Analyze syntenic relationships and regulatory conservation at subtelomeric regions.

  • Identify neo-functionalization events related to SPAC212.08c and its regulation .

• Network visualization and analysis:

  • Create interaction networks that include SPAC212.08c and related factors.

  • Analyze network motifs and topological features to understand regulatory circuits.

  • Validate key network connections through targeted experiments with SPAC212.08c antibody.